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Abstract
Background: Pulmonary function decline is a major contributor to morbidity and mortality among smokers. Post
bronchodilator FEV1 and FEV1/FVC ratio are considered the standard assessment of airflow obstruction. We
performed a genome-wide association study (GWAS) in 9919 current and former smokers in the COPDGene study
(6659 non-Hispanic Whites [NHW] and 3260 African Americans [AA]) to identify associations with spirometric
measures (post-bronchodilator FEV1 and FEV1/FVC). We also conducted meta-analysis of FEV1 and FEV1/FVC
GWAS in the COPDGene, ECLIPSE, and GenKOLS cohorts (total n = 13,532).
Results: Among NHW in the COPDGene cohort, both measures of pulmonary function were significantly associated
with SNPs at the 15q25 locus [containing CHRNA3/5, AGPHD1, IREB2, CHRNB4] (lowest p-value = 2.17 × 10−11), and
FEV1/FVC was associated with a genomic region on chromosome 4 [upstream of HHIP] (lowest p-value = 5.94 × 10
−10);
both regions have been previously associated with COPD. For the meta-analysis, in addition to confirming associations
to the regions near CHRNA3/5 and HHIP, genome-wide significant associations were identified for FEV1 on
chromosome 1 [TGFB2] (p-value = 8.99 × 10−9), 9 [DBH] (p-value = 9.69 × 10−9) and 19 [CYP2A6/7] (p-value = 3.49 × 10−8)
and for FEV1/FVC on chromosome 1 [TGFB2] (p-value = 8.99 × 10
−9), 4 [FAM13A] (p-value = 3.88 × 10−12), 11 [MMP3/12]
(p-value = 3.29 × 10−10) and 14 [RIN3] (p-value = 5.64 × 10−9).
Conclusions: In a large genome-wide association study of lung function in smokers, we found genome-wide
significant associations at several previously described loci with lung function or COPD. We additionally identified a
novel genome-wide significant locus with FEV1 on chromosome 9 [DBH] in a meta-analysis of three study populations.
Keywords: Chronic obstructive pulmonary disease, DBH, FEV1, FEV1/FVC, Genome-wide association study, Spirometry
Background
In the United States, chronic obstructive pulmonary dis-
ease (COPD) is the third leading cause of death [1]. The
major environmental risk factor for COPD is cigarette
smoking, but only a minority of smokers will develop
COPD during their lifetime [2, 3]. COPD risk is most
likely the cumulative result of genetic factors, environ-
mental factors such as cigarette smoking, developmental
factors, and gene-by-environment interactions [4].
A diagnosis of COPD is based on post bronchodila-
tor spirometric measures of the forced expiratory vol-
ume in the first second (FEV1) and the forced vital
capacity (FVC), the total volume of air expired after a
maximal inhalation [5]. The ratio of FEV1/FVC is a
widely used measure of airflow obstruction [3]. Un-
derstanding the genetics underlying these spirometric
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measurements may help increase our knowledge of
the genetics of COPD.
Initial genome wide analyses of spirometric measures
of pulmonary function using family-based linkage ana-
lyses identified broad genomic regions on chromosome
1, 2, 4, 8, and 18 [6]. Subsequent genome wide associ-
ation studies in the Framingham cohort, a population
based sample, identified the HHIP gene as a susceptibil-
ity locus for FEV1/FVC [7]. This Framingham cohort
was combined with several other population based co-
horts forming the CHARGE consortium of greater than
20,000 individuals. This sample, along with the Spiro-
Meta consortium, another population based sample of
over 20,000 individuals, provided the sample for a series
of meta-analyses; one used CHARGE as a discovery
population with subsequent replication in SpiroMeta [8],
a second used SpiroMeta as the discovery population
with selected genotyping in an additional 32,000 indi-
viduals and a pooled meta analysis with the CHARGE
consortium [9], and a third combined CHARGE and
SpiroMeta in the discovery phase (n = 48,201) with
SNP replication in an additional combined population
based sample of 46,411 individuals [10]. The first two
of these meta-analyses confirmed HHIP as a susceptibility
locus for FEV1/FVC and identified multiple additional loci
that were significantly associated with spriometric mea-
sures of pulmonary function. The third meta-analysis
identified 16 new loci for pre bronchodilator pulmonary
function in addition to 10 previously reported loci [10].
To examine the role of smoking on the genetic sus-
ceptibility to spirometric measures of pulmonary func-
tion, the CHARGE/SpiroMeta samples with additional
European ancestry samples totalling more than 30,000
individuals were stratified by smoking status (ever versus
never smokers) [11]. Among smokers, a novel signal on
chromosome 15q25 (CHRNA5/A3/B4 was identified for
airflow obstruction defined as pre bronchodialator FEV1
and FEV1/FVC below the lower limit of normal. This is
the major genomic region for nicotine dependence and
smoking exposure and related traits [12]. More recently
a genome wide study of pulmonary function identified the
CYP2U1 gene [involved in nicotine metabolism], however,
this was not replicated in the CHARGE/SpiroMeta
sample [13].
Given that smoking is the major environmental deter-
minant of pulmonary function decline, we performed a
GWAS of the full quantitative range of post broncho-
dilator pulmonary function in 9919 current and former
smokers of the COPDGene study with complete data
and genome wide genotyping. We hypothesized that we
would identify novel genetic loci and replicate known
genomic regions affecting pulmonary function by per-
forming a GWAS of post bronchodilator spirometric
measures in the COPDGene study, a multi-center
observational study designed to identify genetic factors
associated with risk of COPD. In addition, to insure the
GWAS results are generalizable beyond a single study,
we performed a meta-analysis of post bronchodilator
FEV1 and FEV1/FVC ratio over three similar studies:
the COPDGene, ECLIPSE, and GenKOLS studies.
Characteristics of the 3 studies (COPDGene, ECLIPSE,
and GenKOLS) are given in Table 1. We also assessed
whether different genomic regions were associated with
spirometric measures of pulmonary function separately
among non-Hispanic white (NHW) and African-
American (AA) COPDGene subjects.
Results
COPDGene GWAS in Non-Hispanic Whites
For FEV1 among all NHW COPDGene participants,
several SNPs at the 15q25 locus [near CHRNA3,
CHRNA5, CHRNB4, AGPHD1, and IREB2] reached
genome-wide significance. For FEV1/FVC among all
NHW COPDGene subjects, several SNPs in the same
region on chromosome 15 reached genome-wide signifi-
cance. Tables 2 and 3 show p-values for the most signifi-
cant SNPs in these regions. Additional file 1: Tables S5–S6
list all SNPs with a p-value less than 5 × 10−6.
COPDGene GWAS in African Americans
For both FEV1 and FEV1/FVC among all AA COPDGene
subjects, there were a few SNPs that were genome-wide
significant, but these SNPs were all imputed, with low
minor allele frequency (<5 %), and in a region with no
other non-imputed SNPs. Therefore, we are not confident
that these signals are valid associations. The top SNPs for
these analyses with p-values less than 5 × 10−6 can be
found in the Additional file 1: Tables S1 and S2.
Results from the Meta-Analysis: COPDGene participants
combined with the ECLIPSE and GenKOLS cohorts
For FEV1 and FEV1/FVC, most of the genome-wide sig-
nificant results were again at the 15q25 locus, on
chromosome 4 in FAM13A, and on chromosome 4 near
HHIP. In addition, Table 2 shows other genome-wide
significant findings for FEV1/FVC on chromosome 1
[TGFB2], 9 [DBH] and 19 [CYP2A6, CYP2A7]. Table 3
shows other genome-wide significant findings for FEV1
on chromosome 1 [TGFB2], 11 [MMP3,MMP12] and 14
[RIN3]. The top SNPs for these analyses with p-values
less than 5 × 10−6 can be found in the Additional file 1:
Tables S9 and S10.
Case-only analyses among NHW in COPDGene, AA in
COPDGene, and within the meta-analysis
In addition, we examined the genetic susceptibility to
variation in these pulmonary function phenotypes in
COPD cases only (GOLD stages 2–4) (2820 NHW in
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COPDGene, 821 AA in COPDGene, 1764 NHW in
ECLIPSE, and 863 NHW in GenKOLS). While no SNPs
reached genome-wide significance for either FEV1/FVC
or FEV1 in the case-only analyses, Additional file 1:
Tables S3–S4, S7-S8, and S11–S12 show the top SNPs
for these analyses. Some of the regions that met
genome-wide significance in the entire study popula-
tion had at least nominal evidence for association in
COPD cases only. In addition to the well-established
COPD genetic loci near HHIP, FAM13A, and CHRNA3/5,
the MMP3/MMP12 and DBH regions had P < 0.001
evidence for association to lung function levels within
COPD cases. Power may have been limited in the case-
only analysis, but it is also possible that genetic determi-
nants are more important for the presence/absence of
COPD than for the severity of airflow obstruction within
COPD cases.
Comparison of Findings among AA and NHW
Figure 1 shows how the p-values of the SNPs on chromo-
some 15 [CHRNA3, CHRNA5, CHRNB4, AGPHD1, and
IREB2] compare among the NHW and AA COPDGene
Table 1 Characteristics of COPDGene, ECLIPSE, and GenKOLS Subjects included in genome-wide association analysis. For continuous
variables, the mean is given first followed by the standard deviation
COPDGene NHW COPDGene AA ECLIPSE GenKOLS
Sample size (#COPD cases) 6659 (2812) 3260 (821) 1942 (1764) 1671 (863)
Gender (% male) 47.73 % 44.79 % 66.17 % 58.71 %
Age (years) 62.0 (8.9) 54.6 (7.2) 63.1 (7.6) 60.7 (11.1)
Height (cm) 169.7 (9.5) 171.0 (9.7) 169.7 (9.1) 170.8 (8.9)
BMI (kg/m2) 28.7 (6.0) 29.07 (6.7) 26.8 (5.5) 25.9 (4.6)
Pack-years 47.2 (26.0) 38.3 (21.6) 48.6 (27.7) 26.0 (17.4)
Current Smoking (%) 38.9 % 80.0 % 34.8 % 43.8 %
FEV1 (L) 2.20 (0.95) 2.30 (0.86) 1.50 (0.78) 2.38 (1.10)
FEV1 (% predicted) 74.0 (26.0) 82.0 (23.9) 53.1 (23.2) 72.2 (26.2)
FEV1/FVC 0.64 (0.17) 0.72 (0.14) 0.48 (0.15) 0.65 (0.17)
Notes: FEV1, FEV1 (% predicted), and FEV1/FVC are all based on post-bronchodilator spirometry
Table 2 Genome-wide significant results for FEV1/FVC in the meta-analysis. The SNP with the lowest p value within each region or
gene is listed ordered by chromosome number
SNP Position
(bp)
CHR Nearest Gene Coded
Allele
COPDGene NHW COPDGene AA Meta-Analysis of COPDGene
NHW, COPDGene AA, ECLIPSE
and GenKOLS
Allele
Freq
Beta P Allele
Freq
Beta P Allele
Freq
Beta P
rs72738834 218623888 1 TGFB2 G/G/A 0.79 −0.01 0.00276 0.834 −0.017 5.34E-05 0.81 −0.013 6.51E-09
rs6837671 89873092 4 FAM13A G/G/A 0.60 −0.01 5.18E-06 0.416 0.007 0.03196 0.535 0.013 5.45E-13
rs13141641 145506456 4 LOC646576 (near HHIP) C/C/T 0.60 −0.02 5.72E-09 0.888 −0.015 0.00477 0.632 −0.018 9.52E-20
rs72981684 102724211 11 MMP12 T/T/T 0.88 −0.02 2.46E-07 0.968 −0.024 0.02783 0.114 0.019 3.92E-10
rs72981675 102721251 11 MMP3 T/T/T 0.88 −0.02 2.80E-07 0.968 −0.024 0.02842 0.114 0.019 3.65E-10
rs754388 93115410 14 RIN3 G/G/C 0.82 −0.02 3.17E-07 0.85 −0.01 0.00898 0.83 −0.014 5.54E-09
rs56077333 78899003 15 CHRNA3 A/A/A 0.65 −0.02 4.70E-10 0.816 0.019 6.02E-06 0.314 −0.018 9.55E-20
rs8042849 78817929 15 AGPHD1 C/C/T 0.56 0.02 2.71E-10 0.568 0.008 0.02729 0.561 0.015 2.81E-15
rs17486278 78867482 15 CHRNA5 C/C/A 0.63 0.02 2.28E-09 0.709 0.016 3.14E-06 0.65 0.017 4.48E-20
rs58365910 78849034 15 PSMA4 C/C/T 0.628 0.016 2.28E-09 0.747 0.011 0.00475 0.655 0.015 1.24E-15
rs17487223 78923987 15 CHRNB4 G/T/T 0.616 0.016 9.73E-09 0.882 0.013 0.00999 0.349 −0.016 3.28E-15
rs17484524 78772676 15 IREB2 G/G/A 0.639 0.015 1.86E-07 0.936 0.01 0.138 0.666 0.015 4.83E-13
rs12913260 79071095 15 ADAMTS7 A/A/A 0.59 0.02 1.60E-05 0.88 0.004 0.53 0.371 −0.015 4.82E-08
rs56113850 41353107 19 CYP2A6 T/C/T 0.60 −0.02 2.46E-05 0.562 0.01 0.01955 0.462 0.014 5.19E-09
The “Coded Allele” column refers to the reference allele where the first reference allele is for the COPDGene NHW cohort, the second reference allele is for the
COPDGene AA cohort, and the third reference allele is for the meta-analysis of COPDGene NHW, COPDGene AA, ECLIPSE and GenKOLS. Note that FEV1/FVC was
measured on the proportion scale (0–1) and not the percentage scale (0–100)
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Table 3 Genome-wide significant results for FEV1 in the meta-analysis. The SNP with the lowest p value within each region or gene
is listed ordered by chromosome number
SNP Position
(bp)
CHR Gene/Nearest Gene Coded
Allele
COPDGene NHW COPDGene AA Meta-Analysis of COPDGene
NHW, COPDGene AA, ECLIPSE
and GenKOLS
Allele
Freq
Beta P Allele
Freq
Beta P Allele
Freq
Beta P
rs10863398 218588279 1 TGFB2 A/A/A 0.883 −0.055 0.00539 0.695 −0.07 4.94E-05 0.202 0.067 1.06E-08
rs138641402 145445779 4 LOC646576 (near HHIP) T/T/A 0.641 −0.067 2.28E-06 0.919 −0.09 0.00479 0.668 −0.083 8.99E-15
rs6837671 89873092 4 FAM13A G/G/A 0.595 0.057 1.11E-05 0.416 0.059 0.00024 0.537 0.064 2.89E-13
rs1108581 136505241 9 DBH A/A/A 0.196 0.068 2.29E-05 0.438 0.045 0.00394 0.292 −0.058 8.72E-09
rs56077333 78899003 15 CHRNA3 A/A/A 0.649 0.089 9.49E-11 0.816 0.079 0.00014 0.318 −0.084 5.29E-18
rs8031948 78816057 15 AGPHD1 T/T/T 0.63 0.084 2.61E-10 0.838 0.05 0.02287 0.336 −0.075 2.86E-15
rs17486278 78867482 15 CHRNA5 C/C/A 0.632 0.085 1.44E-10 0.709 0.073 4.31E-05 0.647 0.079 3.48E-18
rs17487223 78923987 15 CHRNB4 T/T/T 0.616 0.081 1.82E-09 0.882 0.066 0.01205 0.353 −0.076 2.06E-14
rs2568494 78740964 15 IREB2 G/G/A 0.367 −0.076 7.25E-09 0.443 −0.028 0.07723 0.545 −0.062 1.66E-12
rs58365910 78849034 15 PSMA4 C/C/T 0.628 0.085 1.65E-10 0.747 0.045 0.01584 0.652 0.072 6.69E-15
rs56113850 41353107 19 CYP2A6 T/C/T 0.596 −0.067 0.00045 0.562 0.048 0.01985 0.458 0.067 1.51E-08
The “Coded Allele” column refers to the reference allele where the first reference allele is for the COPDGene NHW cohort, the second reference allele is for the
COPDGene AA cohort, and the third reference allele is for the meta-analysis of COPDGene NHW, COPDGene AA, ECLIPSE and GenKOLS
Fig. 1 Comparison of chromosome 15 region [CHRNA3/5, IREB2] between NHW (a and c) and AA (b and d) in COPDGene for FEV1 (a and b), and
FEV1/FVC (c and d). Note that there is a similar but narrower and less significant signal in AA
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subjects for both spirometric measures of pulmonary
function. While no single SNP reaches genome-wide
significance in this region among the AA subjects,
there is a region near CHRNA3 with several SNPs
that have p-values in the range of 5x10−6. It appears
that the results among AA are similar to those in
NHW but may not have the power to reach genome-
wide significance due to the smaller sample size. Figure 2
shows qualitatively different association results in the
NHW (highly associated) and AA (not associated) subjects
for the region on chromosome 4 near HHIP, although re-
duced power in the AA subjects could contribute to re-
duced evidence for association.
Comparison to previously published spirometry GWA studies
We considered genome-wide significant results from
a previously published spirometry GWA analysis in
general population samples, which combined the
Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) and SpiroMeta studies [10].
Table 4 shows p-values of these loci from the
CHARGE/SpiroMeta analyses in the COPDGene sub-
populations analysed above. Except for HHIP and
FAM13A, none of the other regions achieved
genome-wide significance (p-value < 5 × 10−8) in the
COPDGene cohort or in the meta-analysis of
COPDGene, GenKOLS, and ECLIPSE. However, quite
a few SNPs had a signal in the same direction as
CHARGE/SpiroMeta and met a nominal levels of sig-
nificance using Bonferroni correction (p-value < 0.0018
for the 28 regions tested) in the meta-analysis of
these three study populations, including SNPs in or
near AGER, MFAP2, RARB, GSTCD, NPNT, SPATA9,
ADAM19, THSD4, and CFDP1.
Fig. 2 Comparison of chromosome 4 region [near HHIP] between NHW (a) and AA (b) for FEV1/FVC. Note that unlike for chromosome 15, there is
not a similar signal in AA, although this could be due to the reduced statistical power in the smaller sample size of AA
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Table 4 Comparison of the current GWA results with the novel genome wide results from the largest GWAS of pre bronchodilator
FEV1 and FEV1/FVC ratio in the CHARGE/SpiroMeta consortium
chr Gene SNP/Position
(bp)
Phenotype CHARGE/SpiroMeta COPDGene NHW COPDGene AA Meta-analysis: COPDGene,
ECLIPSE, and GenKOLS
Coded Allele/Beta/P-value Coded Allele/Allele Frequency/Beta/P-value
1 MFAP2 rs2284746 FEV1/FVC G/-0.04/7.50e-16 G/0.476/0.007/0.012 G/0.807/0.005/0.256 C/0.545/0.007/1.4E-04
17306675
1 TGFB2 rs993925* FEV1/FVC T/0.034/1.16e-08 C/0.33/0.002/0.551 C/0.32/0.004/0.232 T/0..594/0.002/0.3655
218860068
2 TNS1 rs2571445 FEV1 G/0.047/9.83e-11 G/0.393/-0.027/0.03526 G/0/201/0.007/0.7201 A/0.645/-0.015/0.0996
218683154
2 HDAC4 rs12477314 FEV1/FVC T/0.041/1.68e-08 T/0.8/-0.001/0.8196 T/0.963/-0.003/0.683 T/0.187/0.003/0.1802
239877148
3 RARB rs1529672 FEV1/FVC C/-0.048/3.97e-14 C/0.162/0.015/1.88E-05 C/0.20/0.005/0.2018 A/0.82/0.01/6.72E-06
25520582
3 MECOM rs1344555 FEV1 T/-0.034/2.65e-08 T/0.809/0.017/0.293 T/0.799/-0.037/0.07322 T/0.194/-0.008/0.4903
169300219
4 FAM13A rs2045517 FEV1/FVC T/-0.047/2.0e-11 T/0.595/0.012/5.32E-06 T/0.343/0.005/0.1522 T/0.485/-0.012/5.66E-12
89870964
4 GSTCD rs10516526 FEV1 G/0.108/4.75e-14 G/0.935/-0.117/6.16E-06 G/0.951/0.002/0.9647 A/0.694/-0.066/0.00029
106688904
4 NPNT rs17331332 FEV1 G/-0.102/1.11e-12 A/0.933/-0.128/6.16E-06 A/0.979/-0.14/0.03813 A/0.064/0.093/3.19E-06
106808107
4 HHIP rs1032296 FEV1/FVC T/-0.05/3.42e-12 C/0.413/-0.011/1.82E-05 C/0.17/-0.01/0.023 T/0.59/-0.011/1.80E-08
145434688 FEV1 T/-0.047/8.74e-11 A/0.414/-0.045/0.0004 A/0.17/-0.061/0.004 T/0.585/-0.048/2.27E-07
5 SPATA9 rs153916 FEV1/FVC T/-0.031/2.12e-08 C/0.539/-0.008/0.002 C/0.57/-0.008/0.017 T/0.55/-0.008/3.06E-05
95036700
5 HTR4 rs11168048 FEV1/FVC T/-0.047/5.97e-11 T/0.42/0.01/0.0102 T/0.23/-0.002/0.5213 T/0.425/-0.004/0.04823
145479139 FEV1 T/-0.046/2.43e-10 T/0.42/0.03/0.008 T/0.23/0.01/0.548 T/0.428/-0.02/0.01452
5 ADAM19 rs11134779 FEV1/FVC G/-0.042/6.01e-09 G/0.65/0.005/0.086 G/0.411/0.007/0.024 A/0.574/0.006/8.00E-04
156936766
6 AGER rs2070600 FEV1/FVC T/0.126/9.07e-15 A/0.043/0.035/6.22E-08 A/0.01/-0.003/0.849 T/0.31/0.026/2.24e-07
32151443 FEV1 T/0.025/1.271e-12 C/0.043/0.121/0.0001 A/0.01/0.054/0.522 T/0.302/0.081/7.43e-04
6 GPR126 rs3817928 FEV1/FVC G/0.059/2.27e-12 G/0.806/-0.003/0.311 G/0.802/-0.015/3e-04 A/0.807/-0.006/0.01394
142750516
6 LOC153910 rs262129 FEV1/FVC G/0.056/2.91e-13 G/0.704/-0.006/0.043 G/0.19/-0.004/0.3078 A/0.59/-0.005/0.009
142853144
6 ZKSCAN3 rs6903823 FEV1 G/-0.037/2.18e-10 G/0.777/0.013/0.380 G/0.592/-0.049/0.00233 A/0.712/-0.013/0.193
28322296
6 NCR3 rs2857595 FEV1/FVC G/0.037/2.28e-10 G/0.188/0/0.9309 G/0.423/-0.001/0.7777 A/0/-0.001/0.6174
31568469
6 ARMC2 rs2798641 FEV1/FVC T/-0.041/8.35e-09 C/0.191/-0.009/0.005 C/0.053/-0.005/0.505 T/0.825/-0.008
109268050 0.002
9 PTCH1 rs16909859 FEV1/FVC G/0.08/7.45e-10 G/0.075/-0.004/0.432 G/0.295/-0.005/0.156 A/0.67/-0.004/0.1468
98204792
10 CDC123 rs7068966 FEV1/FVC T/0.033/6.13e-13 C0.522/0.002/0.516 T/0.782/-0.008/0.04255 T/0.449/0.003/0.07659
12277992
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A comparison of post and pre bronchodilator FEV1 and
FEV1/FVC among NHW in the COPDGene cohort
Post bronchodilator pulmonary function provides the
ability to separate individuals with reversible pulmonary
function impairments, which is indicative of asthma
from those individuals whose pulmonary function is not
reversible with a bronchodilator. Thus, measuring post
bronchodilator spirometry provides a phenotype that is
more homogeneous with respect to the nature of the
pulmonary function impairment. We hypothesized that
a GWA of post bronchodilator FEV1 and FEV1/FVC
would be similar or more powerful than a GWA of pre
bronchodilator FEV1 and FEV1/FVC. To test this hy-
pothesis, we performed a GWA of pre bronchodilator
FEV1 and FEV1/FVC in the COPDGene cohort among
NHW. The correlation between pre and post broncho-
dilator FEV1 is 0.95 and the correlation between pre and
post bronchodilator FEV1/FVC is 0.98. Additional file 1:
Tables S13 and S14 show the genome wide significant
results for these analyses. The results for the GWA of pre
bronchodilator FEV1 are similar to those of post broncho-
dilator FEV1 among NHW in the COPDGene cohort. 12
SNPs on chromosome 15 [CHRNA3/5] are significantly
associated with post bronchodilator FEV1 where as 8
SNPs in this region are significantly associated with pre
bronchodilator FEV1. For both pre and post bronchodila-
tor FEV1/FVC, the same 8 SNPs on chromosome 15
[CHRNA3/5] and the same 4 SNPS on chromosome 4
[HHIP] are significantly associated with these measures.
These comparisons suggest that previous GWAS [7–13]
are not biased due to the inclusion of individuals with
bronchodilator reversibility. There appears to be only a
modest loss in signal in GWAS of pre bronchodilator
FEV1 compared to post bronchodilator FEV1, and no ap-
parent difference in the signal between pre and post bron-
chodilator FEV1/FVC ratio.
Discussion
To the best of our knowledge, this is the first GWAS of
post bronchodilator pulmonary function. These analyses
were performed in a large cohort of current and former
smokers with the full range of pulmonary function from
normal values to severely impaired. We identified mul-
tiple loci that were genome wide significant for post
bronchodialater FEV1 and FEV1/FVC in both the COPD-
Gene cohort and in the combined meta-analyses.
The most significant association for both FEV1 and
FEV1/FVC among NHW in the COPDGene cohort and in
the combined meta analysis was on chromosome 15q25
[CHRNA3]. This region contains a cluster of nicotinic re-
ceptors that are associated with nicotine dependence,
COPD case status, lower limit of normal for pre broncho-
dilator airway obstruction, lung cancer, and other smoking
related traits [14–23]. A recent analysis by our group sug-
gested this region may both directly and indirectly affect
COPD affection status through nicotine dependence [24].
Other genes within this region in linkage disequilibrium
also demonstrate significant associations with post
bronchodialator FEV1 and FEV1/FVC ratio including
CHRNA5/B4, IREB2, AGPHD1, and ADAMTS7.
Our results suggest common genetic susceptibility to
post bronchodilator FEV1 and FEV1/FVC, pre broncho-
dilator measures of pulmonary function, and COPD affec-
tion status. We confirmed previous GWA association
Table 4 Comparison of the current GWA results with the novel genome wide results from the largest GWAS of pre bronchodilator
FEV1 and FEV1/FVC ratio in the CHARGE/SpiroMeta consortium (Continued)
10 C10orf1 rs11001819 FEV1 G/-0.029/2.98e-12 A/0.524/-0.009/0.493 A/0.661/0.012/0.4849 A/0.45/0.006/0.472
78315224
12 LRP1 rs11172113 FEV1/FVC T/-0.032/1.24e-08 T/0.407/0.006/0.038 T/0.428/0.004/0.1701 T/0.415/-0.004/0.01385
57527283
12 CCDC38 rs1036429 FEV1/FVC T/0.038/2.30e-11 C/0.21/0.006/0.050 C/0.162/0.004/0.399 T/0.809/0.004/0.06425
96271428
15 THSD4 rs12899618 FEV1/FVC G/0.076/1.86e-15 G/0.152/-0.012/0.0007 G/0.12/-0.009/0.0507 A/0.854/-0.009/2.8e-04
71645120
16 MMP15 rs12447804 FEV1/FVC T/-0.038/3.59e-08 T/0.79/-0.002/0.598 T/0.938/-0.001/0.911 T/0.191/0.002/0.528
58075282
16 CFDP1 rs2865531 FEV1/FVC T/0.031/1.77e-11 T/0.592/-0.005/0.078 T/0.351/-0.006/0.05393 A/0.522/-0.005/0.0742
75390316
21 KCNE2 rs9978142 FEV1/FVC T/-0.043/2.65e-08 T/0.849/0.002/0.558 T/0.799/0.002/0.530 A/0.83/0.001/0.677
35652239
The SNP with the lowest p value within each region or gene from the CHARGE/Spirometa consortium is listed ordered by chromosome number [10]. Quite a few
SNPs met a nominal levels of significance using Bonferroni correction (P < 0.0018 for the 28 regions tested)
*In Table 4, while this SNP is not significant in our cohort and meta-analysis, rs12048582 in the TGFB2 gene was genome wide significant (p-value = 6.28E-09)
Lutz et al. BMC Genetics  (2015) 16:138 Page 7 of 11
with HHIP, TGFB2, FAM13A, MMP12, MMP3, CYPA7,
CYP2A6, and RIN3 from previous studies with our results
on post bronchodilator FEV1 and FEV1/FVC.
Significant Spirometry Results associated with COPD
Affection status in COPDGene
In this study, we found that multiple genetic determinants
of COPD affection status were associated with spirometric
measures of lung function in COPDGene. These results are
not at all surprising, since COPD is defined by lung func-
tion thresholds. In the GWAS results of COPD and severe
COPD affection status in COPDGene [25], there was a sig-
nificant association with affection status and SNPs in the
15q25 region [CHRNA3, CHRNA5, CHRNB4, AGPHD1,
and IREB2], HHIP on chromosome 4, FAM13A on chromo-
some 4, TGFB2 on chromosome 1, MMP3/ MMP12 on
chromosome 11, and RIN3 on chromosome 14. We found
evidence for all of these regions as genetic determinants of
spirometric measures in COPDGene as well.
The region on 15q25 contains the genes CHRNA3,
CHRNA5, CHRNB4, AGPHD1, and IREB2, and numer-
ous GWA have shown evidence of association of this re-
gion with COPD, emphysema, lung cancer, and smoking
intensity [14–23]. Regions near HHIP [26–28], FAM13A,
and TGFB2 have been previously associated with lung
function and COPD [8–10, 29]. In addition, SNPs in or
near AGER have previously been reported in association
with lung function and with emphysema [30].
The RIN3 locus on chromosome 14 has not been pre-
viously associated with lung function, although SNPs in
RIN3 were associated with COPD affection status in the
COPDGene study [25]. We identified an association near
RIN3 with FEV1/FVC in the COPDGene cohort. RIN3, a
Rab5 GTPase binding protein, is expressed in many
tissues, including the lung [31, 32].
Significant spirometry GWA results not significantly
associated with affection status in COPDGene
While not previously associated with lung function, DBH
on chromosome 9 has been associated with smoking in-
tensity [33]. Our finding represents the first evidence of
association of this locus with lung function. Although the
SNP identified in this study (rs1108581) does not cause
amino acid residue changes in DBH, gene expression may
be modified either directly or through other variant(s) in
strong LD. This view is supported by evidence that a gen-
etic variant (C-1021T or rs1611115), located upstream of
the DBH translational start site, accounts for 51 % of the
variation in plasma-DBH activity in NHW [33]. SNPs near
CYP2A7 and CYP2A6 on chromosome 19 have been asso-
ciated with lung cancer, cigarette smoking, and COPD
[34, 35]. Notably, both of these loci were significant des-
pite adjustment for cigarette smoking status.
Novel nature of COPDGene study
The COPDGene study is novel in several ways. There
are many subjects with severe and very severe COPD
(GOLD spirometry grades 3–4). There were sufficient
numbers of both AA and NHW subjects to allow rea-
sonable power to detect a genetic association with quan-
titative spirometric measures in these stratified samples.
COPDGene has carefully collected standardized spiro-
metric measures and post-bronchodilator spirometry. In
addition, all COPDGene subjects were former or current
smokers.
Potential limitations
The COPDGene cohort was ascertained based on
smoking status and GOLD stage. Analysing secondary
phenotypes in a case–control study can be biased due
to this ascertainment condition. However, this is only
an issue for SNPs associated with both the ascertain-
ment condition and the secondary phenotype. Since
our analysis focused on measures of pulmonary func-
tion (one of the primary ascertainment conditions)
and adjusted for smoking status, our analysis should
be robust against this sampling bias [36]. While
COPDGene includes both AA and NHW, the sample
size of AA subjects was considerably smaller and
therefore had limited statistical power.
Conclusions
The GWA of lung function measures in COPDGene
identified a novel locus on chromosome 9/DBH among
NHW as being associated with common spirometric
measures, and replicated multiple previously reported
genetic loci for lung function. Further research will be
required to determine the functional genetic variants
within these regions of association.
Methods
COPDGene study subjects
COPDGene is a multi-center study performed in the
United States that has been described in detail previously
[37]. The COPDGene study included 10,192 current
and former smoking participants with at least 10 pack-
years of cigarette smoking history and ages ranging
from 45–81. Table 1 details characteristics of the
COPDGene participants included in the genome-wide
association analysis. We excluded subjects from the
analysis with severe alpha-1 antitrypsin deficiency,
genotyping failure, or spirometric tests which failed
quality control review. This resulted in 9919 subjects
(6659 NHW and 3260 AA). Among these subjects,
there were 3641 COPD cases (2812 NHW and 821 AA)
defined as having Global Initiative for Chronic Ob-
structive Lung Disease (GOLD) spirometry stages 2–4
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with post-bronchodilator FEV1/FVC < 0.70 and FEV1 <
80 % of predicted values.
Post bronchodilator spirometry measurements
Spirometry in COPDGene was performed using a standard-
ized spirometer (EasyOne by ndd Medical Technologies,
Inc, Andover, MA). Spirometry was performed at baseline
and repeated approximately 20 min after two puffs
(180 mcg) of albuterol administered through a spacer.
The analyses in this manuscript focused on the post-
bronchodilator spirometric values. Pulmonary function
measurements were collected according to the American
Thoracic Society/European Respiratory Society guidelines
[38]. Methodology for spirometric measures have been de-
scribed in detail previously [37].
Genotyping, quality control and imputation
All COPDGene subjects were genotyped using the
Illumina HumanOmniExpress by Illumina (San Diego,
CA). Details of genotyping quality control have been
previously described [25]. Imputation on the COPD-
Gene cohorts was performed using MaCH and mini-
mac [39, 40]. Prephasing and imputation were both
performed using 30 rounds and 200 states, with re-
gions divided into 1 megabase and 500 kb flanks. Ref-
erence panels for the NHW and AA subjects were
the 1000 Genomes Phase I v3 European (EUR) and
cosmopolitan reference panels, respectively [41]. Vari-
ants with an R-squared value of ≤ 0.3 were removed
from further analysis. SNPs with minor allele fre-
quency less than 1 % were excluded. Further details
concerning genotyping, quality control, and imput-
ation are posted on the COPDGene website (http://
www.copdgene.org). All SNP genomic locations are
based on the NCBI37/hg19 assembly.
Meta-analysis study populations: ECLIPSE and GenKOLS
The Evaluation of COPD Longitudinally to Identify Pre-
dictive Surrogate Endpoints (ECLIPSE) was a longitu-
dinal, prospective, observational study conducted at 46
clinical centers in 12 countries with genome-wide SNP
data available from 1764 COPD cases and 178 current
or ex-smoking controls [42]. The GenKOLS GWAS
cohort consists of 863 COPD cases and 808 controls
from Bergen, Norway. Genotyping methods and study
descriptions for the GenKOLS and ECLIPSE cohorts
have been described previously [43, 44]. We limited
our analysis in both studies to current or ex-smokers
of European descent.
Statistical analyses
GWA analyses were performed in PLINK (v1.07) and
were stratified by race [45]. Linear regression analyses of
FEV1 and the ratio of FEV1/FVC were adjusted for age,
gender, pack-years, height and genetic ancestry (as sum-
marized by principal components) by including these co-
variates in the model. The primary analyses were
performed on the whole cohort (including smoking con-
trols with normal spirometry and GOLD stages 2 to 4
COPD in all cohorts, and additionally individuals with
unclassified spirometry [FEV1 < 80 % predicted but
FEV1/FVC ≥0.7], and GOLD stage 1 COPD with FEV1 ≥
80 % predicted but FEV1/FVC < 0.7 in COPDGene). A
secondary analysis was limited to only GOLD 2–4 cases.
A fixed effects meta-analysis was performed using
METAL (v 2010-08-01) [46] for FEV1 and FEV1/FVC,
adjusting for the same covariates mentioned above
(age, gender, pack-years, height, genetic ancestry as
summarized by principal components) for the COPD-
Gene, ECLIPSE, and GenKOLS cohorts. Genome-wide
significant associations were defined by P < 5 × 10−8.
Suggestive associations were defined as 5 × 10−7 < P <
5 × 10−8.
Ethics
The COPDGene, ECLIPSE, and GenKOLS studies were
all approved by the respective clinical center institutional
review boards. The COPDGene, ECLIPSE, and Gen-
KOLS studies met IRB protocol approved by the NHLBI
for human subjects research. For the COPDGene study
and the meta-analysis study conducted in this manu-
script, we have obtained IRB approval from the Colorado
Multiple Institutional Review Board (COMIRB) at the
University of Colorado, Colorado School of Public
Health.
Consent
We have obtained written informed consent from the
subjects to participate in these studies. We have ob-
tained written informed consent to publish from the par-
ticipants of the COPDGene, ECLIPSE and GenKOLS
studies and no individual patient data or individual clin-
ical data is presented in this manuscript.
Availability of data and materials
The datasets used in this paper can be found at http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?
study_id=phs000179.v1.p1
Additional file
Additional file 1: The supplement for this manuscript contains
the following information, tables, and figures. The COPD
Foundation funding and a list of the COPDGene and ECLIPSE
investigators are given in the supplement. Tables S1–S12 list the top
SNPs with a p-value <5E-06 for FEV1 and FEV1/FVC for all subjects
and cases only among AA in the COPDGene study, NHW in the
COPDGene study, and in the meta-analysis of the COPDGene, ECLIPSE
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and the GenKOLS studies. Tables S13 and S14 provide a comparison
of genome-wide significant results for pre and post bronchodilator
FEV1 and FEV1/FVC among NHW in the COPDGene study. Figures S1
and S2 are region plots for the genome-wide significant results for FEV1 and
FEV1/FVC, respectively, in the meta-analysis. (DOC 15181 kb)
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